Abstract
Two global epidemics, diabetes mellitus (DM) and tuberculosis (TB), have converged making their control even more challenging. We herein have reviewed metformin’s (MTF) effect on patients with active and latent TB, as well as discussed its newly discovered biological mechanisms in mycobacteria. Mounting evidence suggests that MTF provides better outcomes in TB patients, especially those with DM. The mechanisms by which MTF produces its benefits are multiple. Though metformin’s potential has been proven in patients with DM, larger and more thorough clinical trials, in DM and non-DM-TB patients, need to be conducted. MTF could be added to the arsenal of anti-TB drugs, aiding in the goal of TB eradication worldwide.
| Original language | English |
|---|---|
| Pages (from-to) | 697-702 |
| Number of pages | 6 |
| Journal | Infection |
| Volume | 47 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 1 2019 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
ASJC Scopus Subject Areas
- Microbiology (medical)
- Infectious Diseases
Keywords
- Anti-tuberculous therapy
- Diabetes
- Metformin
- Tuberculosis
Fingerprint
Dive into the research topics of 'Metformin in tuberculosis: beyond control of hyperglycemia'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS